(Q37768280)

22 August 2017

1 reference

title

Vinflunine: review of a new vinca alkaloid and its potential role in oncology (English)

1 reference

22 August 2017

John S Ng

1

1 reference

22 August 2017

publication date

28 June 2010

1 reference

Journal of Oncology Pharmacy Practice

22 August 2017

published in

1 reference

22 August 2017

volume

17

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

209-224

1 reference

Microtubule-associated proteins as targets in cancer chemotherapy

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Introduction. The novel microtubule inhibitor vinflunine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Newer cytotoxic agents: attacking cancer broadly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

21 January 2018

Vinorelbine: an overview

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine: discovery and synthesis of a novel microtubule inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Synthesis and biological evaluation of C-12' substituted vinflunine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

VincaAlkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine: a new microtubule inhibitor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Pharmacokinetics, metabolites, and preclinical safety of vinflunine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine: a novel antitubulin agent in solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Changing face of small-cell lung cancer: real and artifact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Second-line treatment of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Facts and controversies in systemic treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase II study of vinflunine in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Chemotherapy options and new advances in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Neurotoxicity of antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155210373525

21 January 2018

Identifiers

DOI

10.1177/1078155210373525

1 reference

22 August 2017

1 reference